For example, the Children’s Oncology Group (COG) Neuroblastoma Classification Biology Study, ANBL00B1, has been utilizing Age at Diagnosis [3], Clinical Staging (International Neuroblastoma Staging System: INSS) [4], Histopathology (International Neuroblastoma Pathology Classification: INPC) [5–8], MYCN oncogene amplification status [9, 10], DNA index [11], and Chromosomal aberrations [12] for assigning Low, Intermediate, or High Risk protocol to pNT patients from North America, Australia, and New Zealand [13]. The gene discussed is MYCN; the disease is neuroblastoma.